Trial Profile

Preoperative Short Course Radiotherapy With Consolidation Chemotherapies and Camrelizumab Followed by Delayed Surgery in Locally Advanced Rectal Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
Indications Adenocarcinoma; Rectal cancer
Focus Therapeutic Use

Most Recent Events

04 Jun 2024 Results (n=30) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
17 Jan 2021 Short-term Results (Data cut off date- September 8, 2020) of a phase II trial has been presented at the 2021 Gastrointestinal Cancers Symposium
25 Nov 2020 Planned End Date changed from 30 Dec 2022 to 30 Sep 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com